Pular para o conteúdo principal
Ranking Invest

VIR - Vir Biotechnology, Inc.

Segmento: HealthcareVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Análise Ranking Invest

Valor de Mercado
$ 2.02 Bi
IVR
-0.20Índice proprietário de comparação relativa: -0,20.
IVR2
-0.70Leitura proprietária complementar: -70%.
MLL
-0.70Leitura proprietária complementar: -70%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 982.49 Mi

Dívida Líquida

-$ 278.73 Mi

L4T

-$ 251.68 Mi

MM4T

91355.53%

Indicadores Básicos

ROE

-25.62%

Índices de Previsibilidade

Receita Líquida

G2.99

Lucro

D0.69

Margem

E1.52

Índices de Tendência

Receita Líquida

C4.90

Lucro

D-0.20

Margem

F-4.91

Índices de Endividamento

DIV/PAT

-0.28

DIV/L4T

1.11

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.